Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

60;
In the pivotal Phase 3 PROMISE study, 79 percent of treatment-experienced hepatitis C patients treated with simeprevir in combination with pegylated interferon and ribavirin who previously experienced a relapse after prior treatment with pegylated interferon-based therapy achieved the primary endpoint of SVR12 compared to 37 percent of patients treated with placebo plus pegylated interferon and ribavirin. In this sub-analysis, 65 percent of patients with the IL28B TT genotype, 74 percent of patients with a METAVIR score of F4 and 70 percent of patients with genotype 1a HCV treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 19 percent, 26 percent and 28 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively. Among patients with the genotype 1a Q80K polymorphism at baseline, 47 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 30 percent of patients treated with placebo in combination with pegylated interferon and ribavirin.

The most common adverse events in patients treated with simeprevir combined with pegylated interferon and ribavirin in the first 12 weeks were fatigue, headache and influenza-like illness. Three percent and 18 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin experienced on-treatment failure and relapse, respectively, compared to 27 percent and 34 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively.

"We are very proud of the depth and breadth of our clinical trial program," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen Research & Development. "Following last week's positive vote from the FDA's Antiviral Drugs Advisory Committee to recommend approval of simeprevir, we look forward to making simeprevir available to patients living with chronic
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Dompe, a leader in R&D for new therapeutic ... (Recombinant Human Nerve Growth Factor) has been designated as an ... The candidate drug, developed by the research ... the treatment of neurotrophic keratitis, a degenerative corneal disease that ... is currently without a cure. This is the second orphan ...
(Date:7/23/2014)... 23, 2014  ArmaGen, a privately held biotechnology ... severe neurological disorders, announced today that it has ... with Shire plc to develop AGT-182, an investigational ... both the central nervous system (CNS) and somatic ... MPS II, Hunter syndrome is a rare, severe, ...
(Date:7/23/2014)... 23, 2014 Rolta ... für Sadara Chemical Company (Sadara) erhalten zu ... innerhalb des integrierten Chemiekomplexes von Sadara in ... scope im Wert von mehreren Millionen Dollar ... dar, dessen Wert sich ebenfalls auf mehrere ...
Breaking Medicine Technology:Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
... and SYDNEY, Oct. 27, 2011 HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenues of $21.3 million for the third quarter ... increase from $13.8 million in revenues for the same ...
Cached Medicine Technology:Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 2HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 3HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 4HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 5HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010 6
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative ... come up with alternative means to becoming self-sustaining. ... to accomplish this in the July 17 issue ... (HEX). , “We never expected the operating budgets ... Condeluci, an attorney at the law firm Venable ...
(Date:7/23/2014)... DBC Pri-Med LLC , the leading ... more than 260,000 clinicians and the University of South ... national continuing medical education (CME) curriculum to educate and ... ultrasound and how to utilize these technologies at the ... Carolina School of Medicine will deliver its first education ...
(Date:7/23/2014)... TeraGanix has recently announced the ... located only 4.5 miles off of highway I-8. The new ... accessibility for businesses in the Arizona region that use its ... Its Casa Grande location is only 1 hour away from ... from Phoenix. With over 26 million acres of agricultural ...
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 According ... residential real estate transactions throughout the region, the ... trends in June. Homes are selling quickly throughout the ... parts of the region. The Northern Virginia market includes ... Prince William counties. , The Northern Virginia region saw ...
(Date:7/23/2014)... Townsend Security, a leading authority in data ... security solutions now support two factor authentication. This major ... relying on passwords as their only authentication mechanism. , ... Two Factor Authentication software with the following Alliance ... Alliance AES/400 – High performance, NIST validated AES encryption ...
Breaking Medicine News(10 mins):Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 2Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 3Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2Health News:Townsend Security Brings Two Factor Authentication to Leading IBM i Security Solutions 2
... April 24 Foundation for,Biomedical Research (FBR) Board Chairman ... the highest civilian honor Congress can,bestow, on Wednesday., ... the world of science,are few, but they are iconic ... said President George W. Bush. "Today we gather to ...
... and Employment,Discrimination, BAYSIDE, N.Y., April 24 ... hailed today,s vote in the,United States Senate ... (GINA), to ban genetic discrimination in,health insurance ... GINA,in April 2007., "TSA has worked ...
... First Patient Receives Cimzia(R) Dose through CIMplicity(TM) within Two ... ... April 24 UCB announced today the launch of its,CIMplicity(TM) ... to severe Crohn,s disease. CIMplicity(TM) provides,Cimzia(R) patients and their caregivers ...
... at Long Beach Veterans Administration Hospital, LONG ... Administration will honor Dr. Richard Merkin, President of,Heritage ... of American,war veterans. The VA, in collaboration with ... research study aimed at,examining diabetic ulcers in veterans. ...
... at 11:00,am, Family Research Council will present a lecture ... Health Policy Studies. Mr.,Moffit will discuss why health care ... applications in medicine, e.g. the,right to choose a pro-life ... the life of a loved one. To have these ...
... of Seniors Act, WASHINGTON, April 24 The ... to preventing,unintentional home injuries, applauds today,s enactment of the ... President Bush yesterday, comes,at a critical time when each ... and about 30 percent of those who fall require ...
Cached Medicine News:Health News:Michael E. DeBakey Receives Congressional Gold Medal 2Health News:Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 3Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 4Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 5Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 6Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 7Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:President Signs Elder Falls Bill Into Law 2
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: